These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 10801955)

  • 21. I hear you knockin' (but you can't come in): potent new HIV therapies are shutting out opportunistic infections.
    Fichtenbaum CJ
    Res Initiat Treat Action; 1998 Jul; 4(4):3-7. PubMed ID: 11365645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy.
    Kaplan JE; Hanson D; Dworkin MS; Frederick T; Bertolli J; Lindegren ML; Holmberg S; Jones JL
    Clin Infect Dis; 2000 Apr; 30 Suppl 1():S5-14. PubMed ID: 10770911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum thymulin in human zinc deficiency.
    Prasad AS; Meftah S; Abdallah J; Kaplan J; Brewer GJ; Bach JF; Dardenne M
    J Clin Invest; 1988 Oct; 82(4):1202-10. PubMed ID: 3262625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
    Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
    N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impaired CD4 T-cell count response to combined antiretroviral therapy in antiretroviral-naive HIV-infected patients presenting with tuberculosis as AIDS-defining condition.
    Cingolani A; Cozzi Lepri A; Castagna A; Goletti D; De Luca A; Scarpellini P; Fanti I; Antinori A; d'Arminio Monforte A; Girardi E
    Clin Infect Dis; 2012 Mar; 54(6):853-61. PubMed ID: 22157323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.
    Mussini C; Pezzotti P; Govoni A; Borghi V; Antinori A; d'Arminio Monforte A; De Luca A; Mongiardo N; Cerri MC; Chiodo F; Concia E; Bonazzi L; Moroni M; Ortona L; Esposito R; Cossarizza A; De Rienzo B
    J Infect Dis; 2000 May; 181(5):1635-42. PubMed ID: 10823763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Melatonin administration in tumor-bearing mice (intact and pinealectomized) in relation to stress, zinc, thymulin and IL-2.
    Mocchegiani E; Perissin L; Santarelli L; Tibaldi A; Zorzet S; Rapozzi V; Giacconi R; Bulian D; Giraldi T
    Int J Immunopharmacol; 1999 Jan; 21(1):27-46. PubMed ID: 10411280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of oral zinc administration on prolactin and thymulin circulating levels in patients with chronic renal failure.
    Travaglini P; Moriondo P; Togni E; Venegoni P; Bochicchio D; Conti A; Ambroso G; Ponticelli C; Mocchegiani E; Fabris N
    J Clin Endocrinol Metab; 1989 Jan; 68(1):186-90. PubMed ID: 2909550
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Zinc, thymic endocrine activity and mitogen responsiveness (PHA) in piglets exposed to maternal aflatoxicosis B1 and G1.
    Mocchegiani E; Corradi A; Santarelli L; Tibaldi A; DeAngelis E; Borghetti P; Bonomi A; Fabris N; Cabassi E
    Vet Immunol Immunopathol; 1998 Apr; 62(3):245-60. PubMed ID: 9643458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination.
    López-Palomo C; Martín-Zamorano M; Benítez E; Fernández-Gutiérrez C; Guerrero F; Rodríguez-Iglesias M; Girón-González JA
    J Med Virol; 2004 Apr; 72(4):517-24. PubMed ID: 14981752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo and in vitro studies of thymulin in marginally zinc-deficient mice.
    Dardenne M; Savino W; Wade S; Kaiserlian D; Lemonnier D; Bach JF
    Eur J Immunol; 1984 May; 14(5):454-8. PubMed ID: 6609827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prospective study of highly active antiretroviral therapy in Indian human immunodeficiency virus positive patients.
    Rajesh R; Vidyasagar S; Varma DM; Naik A; Hegde BM; Guddattu V; Kamath A
    Int J Risk Saf Med; 2013 Jan; 25(1):53-65. PubMed ID: 23442298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study.
    Furrer H; Egger M; Opravil M; Bernasconi E; Hirschel B; Battegay M; Telenti A; Vernazza PL; Rickenbach M; Flepp M; Malinverni R
    N Engl J Med; 1999 Apr; 340(17):1301-6. PubMed ID: 10219064
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. When to initiate highly active antiretroviral therapy in low-resource settings: the Moroccan experience.
    Loubiere S; el Filal KM; Sodqi M; Loundou A; Luchini S; Cleary S; Moatti JP; Himmich H
    Antivir Ther; 2008; 13(2):241-51. PubMed ID: 18505175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma zinc level and thymic hormone activity in young cancer patients.
    Mocchegiani E; Paolucci P; Granchi D; Cavallazzi L; Santarelli L; Fabris N
    Blood; 1994 Feb; 83(3):749-57. PubMed ID: 8298137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.
    Ledergerber B; Mocroft A; Reiss P; Furrer H; Kirk O; Bickel M; Uberti-Foppa C; Pradier C; D'Arminio Monforte A; Schneider MM; Lundgren JD;
    N Engl J Med; 2001 Jan; 344(3):168-74. PubMed ID: 11188837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Report on the Fifth Conference on Retroviruses and Opportunistic Infections.
    Soloway B
    AIDS Clin Care; 1998 Apr; 10(4):27-9. PubMed ID: 11365150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Impact of zidovudine treatment and the pneumocystis carinii prophylaxis in natural history of patients with HIV infection].
    Sáiz Hervas E; Castilla Castellano V; Miquel Plaza J; Benito Blanco AM; Martín Llorens MM; Pastor de Blas M; Izquierdo P; Muñoz Jareño MA; Sierra A; Nieto MA; Moreno Collado AM; Fraguas C
    An Med Interna; 1998 Mar; 15(3):132-7. PubMed ID: 9580410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.